Zürcher Kantonalbank (ZKB) is a Swiss cantonal bank and one of Switzerland's most active venture capital investors, providing equity capital and convertible loans to innovative start-ups and scale-ups across sectors including biotech, cleantech, deep tech, healthcare, ICT, and fintech. Founded in 1870 and headquartered in Zurich, ZKB has supported over 250 start-ups with more than CHF 180 million in risk capital.
Average disclosed round size is $8.3M (across 7 rounds with reported amounts).
Portfolio
18
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Team
Daniel Previdoli
Head of Products, Services & Direct Banking
Dr. Martin Bardenhewer
Chief Financial Officer
Florence Schnydrig Moser
Head of Private Banking, Deputy Chief Executive Officer
Hjalmar Schröder
Chief Risk Officer
Susanne Thellung
Head of Retail Clients
Urs Baumann
Chief Executive Officer (CEO)
Christian Sarwa
Managing Director Private Equity
Christian Bader
Senior equity analyst
Iwan Deplazes
Leiter Asset Management
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| SSynendos | Series A | — | Nov 2020 |
 Nezasa | Growth | $4.7M | Jan 2020 |
 Ava | Series A | $9.7M | Nov 2016 |
| TTestmate Health | Seed | $6M | — |
 Bcomp | Series C | — | — |
 Nagi Bioscience | Series A | — | — |
 Lunaphore | Series B | $11.6M | — |
 Unbound Potential | Pre-Seed | $14.4M | — |
 Hylomorph | Series B | $5.2M | — |
 9T Labs | Series A | — | — |
 FenX | Series A | — | — |
| VVersantis | Series A | — | — |
 APIAX | Series A | $6.6M | — |
| LLymphatica | Series B | — | — |
 AVAtronics | Seed | — | — |
 Hylomorph | Unknown | — | — |
 Bcomp | Series C | — | — |
 Memo Therapeutics | Series B | — | — |
Top Co-Investors
Last updated: 9 September 2026